Cell therapies, in particular, chimeric antigen receptor modified T cells (CAR-T), are showing enormous therapeutic promise, with cancer remission rates over 80 percent. This alone is forcing cell therapy manufacturing companies to develop strategies to build and scale up production at levels never contemplated before.
Choose Your Location
To customize your experience, select an IPS region or country to view specific information based on your location.
- United States
- All Other Countries
You’ve chosen as your location.
Thank you for choosing a location. This will help us show the information that means to most to you. Continue to the homepage to view featured projects, and happenings specific to your location.